Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Share-based Compensation (2018 - 2025)

Historic Share-based Compensation for TransMedics (TMDX) over the last 8 years, with Q3 2025 value amounting to $9.1 million.

  • TransMedics' Share-based Compensation rose 1500.5% to $9.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.2 million, marking a year-over-year increase of 3566.94%. This contributed to the annual value of $33.2 million for FY2024, which is 6787.43% up from last year.
  • Per TransMedics' latest filing, its Share-based Compensation stood at $9.1 million for Q3 2025, which was up 1500.5% from $9.4 million recorded in Q2 2025.
  • In the past 5 years, TransMedics' Share-based Compensation registered a high of $10.8 million during Q4 2024, and its lowest value of $1.1 million during Q1 2021.
  • Its 5-year average for Share-based Compensation is $5.1 million, with a median of $5.0 million in 2023.
  • Its Share-based Compensation has fluctuated over the past 5 years, first soared by 18883.12% in 2021, then soared by 1500.5% in 2025.
  • Over the past 5 years, TransMedics' Share-based Compensation (Quarter) stood at $2.0 million in 2021, then surged by 50.68% to $3.0 million in 2022, then skyrocketed by 91.37% to $5.7 million in 2023, then surged by 88.1% to $10.8 million in 2024, then fell by 15.15% to $9.1 million in 2025.
  • Its Share-based Compensation was $9.1 million in Q3 2025, compared to $9.4 million in Q2 2025 and $9.0 million in Q1 2025.